Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.…
PacBio to Participate in the Piper Sandler 38th Annual Healthcare Conference
Pacific Biosciences of California (NASDAQ: PACB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 485 employees.
The shares were at 1.630 USD on 20 November 2026, down 8.4% over 52 weeks. Its 52-week range is 1.070 USD to 3.435 USD: the price is 52.5% below the high and 52.3% above the low.
Its market capitalisation is 508.95M USD.
Pacific Biosciences of California reports an operating margin of -333.0% and revenue up 5.5% year over year.
Its debt exceeds its cash by 508.95M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 2.743 USD is 68.3% above the current price. The next earnings report is expected on 11 February 2027.